Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer.

Masashi SawadaAkiyoshi KasugaTakafumi MieTakaaki FurukawaTakanobu TaniguchiKoshiro FukudaYuto YamadaTsuyoshi TakedaRyo KanataMasato MatsuyamaTakashi SasakiMasato OzakaNaoki Sasahira

Published in: BMC cancer (2020)

The mFFX showed to be a tolerable second-line treatment for MPC after GnP failure. Our prognostic model might be useful for deciding whether mFFX is indicated in this setting.

Keyphrases

locally advanced
squamous cell carcinoma
small cell lung cancer
radiation therapy
stem cells
advanced non small cell lung cancer
combination therapy
mesenchymal stem cells